Fact checked byRichard Smith

Read more

October 28, 2022
3 min read
Save

Diabetes may be ‘no longer equivalent to CVD’ as a CV risk factor

Fact checked byRichard Smith
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Adults with diabetes in Ontario, Canada, had a greater reduction in risk for cardiovascular events from 1994 to 2014 compared with adults with prior CV disease, according to a research letter published in JAMA.

Perspective from Robert H. Eckel, MD

In findings from a retrospective population-based cohort study, the risk for CV events among adults with diabetes, prior CVD or both diabetes and prior CVD was greater compared with adults with neither condition in both 1994 and 2014. However, the rate of CV events declined for all adults during that period, and those with diabetes had the largest decline in event rate.

Calvin Ke, MD, PhD
Ke is an assistant professor in the department of medicine at the University of Toronto.

“Twenty-five years ago, diabetes was first described as a ‘CV risk equivalent,’” Calvin Ke, MD, PhD, assistant professor in the department of medicine at the University of Toronto, told Healio. “This term means that people with diabetes had a similar risk of a CV event as those with prior CVD. We looked at 25 years of data from Ontario, Canada. In 1994, people with diabetes had double the risk of CV events compared to people without diabetes or prior CVD. This doubling in risk was similar to people with prior CVD. By 2014, people with diabetes had a 58% increase in CV risk, while people with prior CVD disease still had around double the CV risk compared to disease-free individuals. This evidence suggests that modern approaches have had a major impact on reducing CV complications in diabetes. Still, diabetes remains a strong CV risk factor.”

Diabetes and CVD increase risk for CV events

Ke and colleagues conducted an analysis of administrative health care data from Ontario, Canada, of adults aged 20 to 84 years. Data were extracted for adults alive in each of the following years: 1994, 1999, 2004, 2009 and 2014. Researchers selected a sample of 25% of eligible adults for each index year and followed them for up to 5 years. Within each year, adults were identified as having diabetes, prior CVD, both diabetes and prior CVD, or neither condition. Adults were considered to have had a CV event if they were hospitalized for acute myocardial infarction or stroke, or died of any cause.

From 1994 to 2014, the prevalence of diabetes increased from 3.1% to 9%, and the prevalence of CVD increased from 2.5% to 3.7%.

In 1994, adults with diabetes (RR = 2.06; 95% CI, 2.02-2.1), prior CVD (RR = 2.16; 95% CI, 2.12-2.21) and diabetes plus prior CVD (RR = 3.81; 95% CI, 3.69-3.93) had a higher risk for CV events compared with adults who did not have diabetes or CVD.

CV risk with diabetes reduced over 25 years

In 2014, adults with diabetes (RR = 1.58; 95% CI, 1.56-1.61), prior CVD (RR = 2.06; 95% CI, 2.02-2.1) and both diabetes and prior CVD (RR = 3.1; 95% CI, 3.04-3.17) still had a higher risk for CV events than adults with neither condition. However, CV event rates decreased for all adults, regardless of condition. Adults with diabetes had the largest reduction in event rates in 2014 compared with 1994 (RR = 0.49), followed by adults with neither condition (RR = 0.63), adults with prior CVD (RR = 0.66) and adults with diabetes and prior CVD (RR = 0.69).

“These results suggest that diabetes is still an important CV risk factor but no longer equivalent to CVD — a change that likely reflects the use of modern, multifactorial approaches to diabetes,” the researchers wrote.

Ke said the use of statins, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers to reduce CV complications, improvements in glycemic management and diabetes screening, and the emergence of GLP-1 receptor agonists and SGLT2 inhibitors are all factors that may have contributed to the reduction in CV events.

“Clinically, these findings suggest that changes in practice we have enacted over the past 25 years have probably helped shift trends in the right direction,” Ke said. “Our results are consistent with modern approaches to CV risk reduction being taken up widely and implemented effectively into clinical practice. At the same time, we observed that diabetes remains a strong CV risk factor, and efforts are required to better prevent and manage diabetes and CVD.”

For more information:

Calvin Ke, MD, PhD, can be reached at calvin.ke@utoronto.ca.